Department of Orthopedics, Changzheng Hospital, Second Military Medical University, 415 Fengyang Road, Shanghai 200003, People's Republic of China; College of basic medicine, Second Military Medical University, 800 Xiangyin Road, Shanghai 200433, People's Republic of China.
Department of Orthopedics, Changzheng Hospital, Second Military Medical University, 415 Fengyang Road, Shanghai 200003, People's Republic of China.
Metabolism. 2021 Jun;119:154767. doi: 10.1016/j.metabol.2021.154767. Epub 2021 Mar 20.
BACKGROUND: Obesity and osteoporosis frequently coexist, and might have a causal relationship. Gut microbiota, associated with both lipid and bone metabolism, plays an important role in the pathogenesis of excessive fat accumulation and bone loss. The improvement of intestinal flora by prebiotics was a promising strategy for ameliorating obesity-related bone loss. METHODS: Obesity model was established by feeding mice with high fat diet (HFD) for 16 weeks. Fructooligosaccharides (FOS) and/or galactooligosaccharides (GOS) were daily gavaged to mice. Osteoblastic, adipocytic, and osteoclastic differentiation was performed on primary cells isolated from experimental mice. The composition of gut flora was evaluated by 16s rDNA sequencing. Expression of intestinal junction proteins was assessed by qPCR and immunohistochemistry. Cytokine levels were measured by qPCR. RESULTS: Long-term HFD caused decreased bone mass in mice, which was associated with decreased osteogenesis, increased osteoclastogenesis, and excessive adipogenesis. FOS/GOS treatment significantly alleviated HFD-induced bone loss and reversed the imbalanced differentiation of osteoblasts, adipocytes, and osteoclasts. In addition, our study showed that FOS/GOS administration ameliorated microbiota dysbiosis (manifested as enhanced Firmicutes:Bacteriodetes ratio and reduced biodiversity), downregulated expression of intestinal junction proteins (including Claudin1, Claudin15, ZO-1, and JAM-A), and increased inflammatory cytokines (including TNFα, IL6, and IL17) in HFD-fed mice. CONCLUSION: Long-term HFD led to decreased bone mass, with microbiota dysbiosis, leaky gut, and systemic inflammation. The administration of FOS/GOS could significantly increase biodiversity and SCFA concentrations of intestinal flora in HFD fed mice, then reverse high gut permeability and inflammatory cytokines, in the end protect against HFD induced osteopenia.
背景:肥胖症和骨质疏松症经常同时存在,并且可能存在因果关系。与脂质和骨代谢相关的肠道微生物群在过度脂肪积累和骨丢失的发病机制中起着重要作用。通过使用益生元来改善肠道菌群是改善肥胖相关骨丢失的一种有前途的策略。
方法:通过用高脂肪饮食(HFD)喂养小鼠 16 周来建立肥胖模型。每天给小鼠灌胃果寡糖(FOS)和/或半乳糖寡糖(GOS)。在实验小鼠分离的原代细胞上进行成骨细胞、脂肪细胞和成骨细胞分化。通过 16s rDNA 测序评估肠道菌群的组成。通过 qPCR 和免疫组织化学评估肠道连接蛋白的表达。通过 qPCR 测量细胞因子水平。
结果:长期 HFD 导致小鼠骨量减少,这与成骨减少、破骨细胞增加和脂肪生成过多有关。FOS/GOS 治疗可显著缓解 HFD 诱导的骨丢失,并逆转成骨细胞、脂肪细胞和成骨细胞的失衡分化。此外,我们的研究表明,FOS/GOS 给药可改善微生物群失调(表现为厚壁菌门:拟杆菌门比例增加和生物多样性减少),下调肠道连接蛋白(包括 Claudin1、Claudin15、ZO-1 和 JAM-A)的表达,并增加 HFD 喂养小鼠的炎症细胞因子(包括 TNFα、IL6 和 IL17)。
结论:长期 HFD 导致骨量减少,同时存在微生物群失调、肠漏和全身炎症。在 HFD 喂养的小鼠中,FOS/GOS 的给药可显著增加肠道菌群的生物多样性和 SCFA 浓度,然后逆转高肠道通透性和炎症细胞因子,最终防止 HFD 引起的骨质疏松症。
Int J Obes (Lond). 2018-9-21
Compr Physiol. 2025-8
Adv Exp Med Biol. 2025
J Orthop Translat. 2025-1-21
Curr Nutr Rep. 2025-1-31
Gut Microbes. 2025-12